| Chapter title |
Vismodegib
|
|---|---|
| Chapter number | 9 |
| Book title |
Small Molecules in Oncology
|
| Published in |
Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer, January 2018
|
| DOI | 10.1007/978-3-319-91442-8_9 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-991441-1, 978-3-31-991442-8
|
| Authors |
Frank Meiss, Hana Andrlová, Robert Zeiser, Meiss, Frank, Andrlová, Hana, Zeiser, Robert |
| Abstract |
Vismodegib (GDC-0449, Erivedge®) is a small molecule antagonist of the hedgehog (Hh) pathway that binds to smoothened (SMO) and leads to inhibition of an aberrant activation of the Hh pathway. Dysregulated Hh signaling results in uncontrolled proliferation in basal cell carcinoma (BCC) and has also been found present in medulloblastoma, and many other cancers such as those of gastrointestinal tract, brain, lung, breast, and prostate. In January 2012, vismodegib became the first agent to target the Hh pathway to receive approval by the United States Food and Drug Administration (FDA) and in July 2013 approval by the European Medicines Agency (EMA) followed for the treatment of adult patients with symptomatic metastatic BCC, or locally advanced BCC inappropriate for surgery or radiotherapy. The role of vismodegib in other malignancies than BCC has still to be investigated. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 25 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 3 | 12% |
| Student > Postgraduate | 2 | 8% |
| Student > Bachelor | 2 | 8% |
| Lecturer | 1 | 4% |
| Student > Doctoral Student | 1 | 4% |
| Other | 3 | 12% |
| Unknown | 13 | 52% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 20% |
| Biochemistry, Genetics and Molecular Biology | 4 | 16% |
| Neuroscience | 1 | 4% |
| Agricultural and Biological Sciences | 1 | 4% |
| Unknown | 14 | 56% |